PMID- 21551511
OWN - NLM
STAT- MEDLINE
DCOM- 20111118
LR  - 20220321
IS  - 1468-2060 (Electronic)
IS  - 0003-4967 (Linking)
VI  - 70
IP  - 8
DP  - 2011 Aug
TI  - ASDAS, BASDAI and different treatment responses and their relation to biomarkers 
      of inflammation, cartilage and bone turnover in patients with axial 
      spondyloarthritis treated with TNFalpha inhibitors.
PG  - 1375-81
LID - 10.1136/ard.2010.138883 [doi]
AB  - OBJECTIVES: To investigate the relation between ankylosing spondylitis disease 
      activity score (ASDAS), Bath ankylosing spondylitis disease activity index 
      (BASDAI) and treatment response and biomarkers of inflammation (C-reactive 
      protein (CRP), interleukin-6 (IL-6), YKL-40), angiogenesis (vascular endothelial 
      growth factor (VEGF)), cartilage (C-terminal crosslinking telopeptide of type II 
      collagen (CTX-II), matrix metalloproteinase-3 (MMP-3), total aggrecan, cartilage 
      oligomeric matrix protein) and bone (C-terminal crosslinking telopeptide of type 
      I collagen, osteocalcin) turnover in 60 patients with axial spondyloarthritis 
      initiating tumour necrosis factor alpha (TNFalpha) inhibitor therapy. METHODS: ASDAS 
      (CRP-based), BASDAI and biomarkers were determined before and seven times during 
      46 weeks of TNFalpha inhibitor therapy. RESULTS: Very high ASDAS were associated with 
      high levels of inflammatory biomarkers, while high BASDAI were not related to any 
      biomarkers. Mixed modeling demonstrated significant longitudinal associations 
      between ASDAS and IL-6, VEGF, MMP-3 and osteocalcin and between BASDAI and CRP, 
      IL-6 and VEGF. Major improvement in ASDAS was associated with larger percentage 
      decreases in biomarkers of inflammation, angiogenesis, MMP-3 and increases in 
      aggrecan and osteocalcin. BASDAI response was associated with larger decreases in 
      CRP and IL-6. Biomarkers with moderate/high differences in responsiveness for 
      major versus no/clinically important improvement in ASDAS were CRP, IL-6, VEGF, 
      aggrecan and osteocalcin, and VEGF and CTX-II for BASDAI response versus 
      non-response. CONCLUSION: Levels and changes of 10 biomarkers in patients with 
      axial spondyloarthritis during anti-TNFalpha therapy were documented. Construct 
      validity and responsiveness of IL-6, VEGF, MMP-3, total aggrecan and osteocalcin 
      were demonstrated. ASDAS was more associated with these biomarkers than BASDAI, 
      and may better reflect the inflammatory disease processes. ClinicalTrials.gov 
      identifier NCT00133315.
FAU - Pedersen, Susanne Juhl
AU  - Pedersen SJ
AD  - Rheumatologic Research Unit, Glostrup University Hospital, Copenhagen, Denmark. 
      susanne_juhl_ped@dadlnet.dk
FAU - Sorensen, Inge Juul
AU  - Sorensen IJ
FAU - Garnero, Patrick
AU  - Garnero P
FAU - Johansen, Julia Sidenius
AU  - Johansen JS
FAU - Madsen, Ole Rintek
AU  - Madsen OR
FAU - Tvede, Niels
AU  - Tvede N
FAU - Hansen, Michael Sejer
AU  - Hansen MS
FAU - Thamsborg, Gorm
AU  - Thamsborg G
FAU - Andersen, Lis Smedegaard
AU  - Andersen LS
FAU - Majgaard, Ole
AU  - Majgaard O
FAU - Loft, Anne Gitte
AU  - Loft AG
FAU - Erlendsson, Jon
AU  - Erlendsson J
FAU - Asmussen, Karsten
AU  - Asmussen K
FAU - Jurik, Anne Grethe
AU  - Jurik AG
FAU - Moller, Jakob
AU  - Moller J
FAU - Hasselquist, Maria
AU  - Hasselquist M
FAU - Mikkelsen, Dorrit
AU  - Mikkelsen D
FAU - Skjodt, Thomas
AU  - Skjodt T
FAU - Lambert, Robert
AU  - Lambert R
FAU - Hansen, Annette
AU  - Hansen A
FAU - Ostergaard, Mikkel
AU  - Ostergaard M
LA  - eng
SI  - ClinicalTrials.gov/NCT00133315
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20110508
PL  - England
TA  - Ann Rheum Dis
JT  - Annals of the rheumatic diseases
JID - 0372355
RN  - 0 (Angiogenesis Inducing Agents)
RN  - 0 (Antirheumatic Agents)
RN  - 0 (Biomarkers)
RN  - 0 (Inflammation Mediators)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 9007-41-4 (C-Reactive Protein)
SB  - IM
MH  - Adult
MH  - Angiogenesis Inducing Agents/blood
MH  - Antirheumatic Agents/pharmacology/*therapeutic use
MH  - Biomarkers/blood
MH  - Bone Remodeling/drug effects/physiology
MH  - C-Reactive Protein/metabolism
MH  - Cartilage, Articular/drug effects/metabolism
MH  - Female
MH  - Humans
MH  - Inflammation Mediators/*blood
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - *Severity of Illness Index
MH  - Spondylarthritis/*drug therapy/metabolism
MH  - Treatment Outcome
MH  - Tumor Necrosis Factor-alpha/*antagonists & inhibitors
MH  - Young Adult
EDAT- 2011/05/10 06:00
MHDA- 2011/12/13 00:00
CRDT- 2011/05/10 06:00
PHST- 2011/05/10 06:00 [entrez]
PHST- 2011/05/10 06:00 [pubmed]
PHST- 2011/12/13 00:00 [medline]
AID - ard.2010.138883 [pii]
AID - 10.1136/ard.2010.138883 [doi]
PST - ppublish
SO  - Ann Rheum Dis. 2011 Aug;70(8):1375-81. doi: 10.1136/ard.2010.138883. Epub 2011 
      May 8.